FindTrial
Sign In

Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma. - Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glau

Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glaucoma. - Randomised controlled trial of intravitreal Bevacizumab vs. conventional treatment for rubeotic glau

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2007-000585-21-IE
Enrollment
20
Registered
2007-02-06
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rubeotic glaucoma secondary to ischaemic proliferative retinopathies

Interventions

Trade Name: Avastin Product Name: Avastin (bevacizumab) Pharmaceutical Form: Injection*

Sponsors

Royal Victoria Eye and Ear hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients with rubeotic glaucoma ( iris or angle neovascularisation and intraocular pressure > 21 mmHg) Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) yes F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: Only eye Women of childbearing potential

Design outcomes

Primary

MeasureTime frame
Main Objective: To assess the effectiveness of intravitreal bevacizumab in treating rubeotic glaucoma when compared with conventional treatment. Primary outcomes: 1. Iris neovascularisation 2. IOP 3. IOP medications 4. Pain 5. Visual acuity 6. Need for enucleation ;Secondary Objective: Secondary outcomes: Quality of life, OCT.;Primary end point(s): Primary end points: 1. Iris neovascularisation 2. IOP 3. IOP medications 4. Pain 5. Visual acuity 6. Need for enucleation—

Countries

Ireland

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026